Venture

EpiTET’s novel, oral targets has the potential to revolutionize the way we treat a number of chronic inflammatory conditions including endometriosis, metabolic dysfunction (MASH), cancers, and other conditions.  Our approach selectively eliminates pathogenic macrophages, the key drivers of chronic inflammation and disease micro-environment without suppressing overall immunity.

EpiTET Team:

Erika Smith